Cevaretigene ritoparvovec

瑞哌西沃基

Report date: 2023/12/01 20:06:44

Base Information

Drug NameCevaretigene ritoparvovec
Drug Alias NameAAV2/5-OPTIRPE65AAV2/5-RPE65P/OPTIRPE65
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/5 vector
Mechanisms of ActionRetinoid isomerohydrolase stimulantsGene transference
TargetsRetinoid isomerohydrolase
Therapy Area/IndicationsLeber Congenital Amaurosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAthena PharmaMeiragtx Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMeiragtx Uk Ii Ltd
Active IndicationsN/A
Inactive IndicationsLeber Congenital Amaurosis

Other Information

ATC CodeN/A
Related LinksN/A